Edaravone Improves Streptozotocin-Induced Memory Impairment via Alleviation of Behavioral Dysfunction, Oxidative Stress, Inflammation, and Histopathological Parameters

Figure 10

Hippocampus sections in control and treatments groups (). H&E staining. ×100. (a) Control group received of STZ and/or EDV; (b) DON group received 1 mg/kg of Donepezil; (c) Memantine group received 5 mg/kg of Memantine; (d) EDV group received 10 mg/kg of EDV; (e) ALZ group received 3 mg/kg, which received ICV-STZ two times in 48 hours interval and receiving ICV-STZ once: basophilic necrotic neuron (yellow arrows), microglial nodule (blue arrow), and mild vacuolization (green arrows); (f) ALZ + EDV group received 3 mg/kg of ICV-STZ in 48 hours interval; 24 hours later administered with 5 mg/kg of EDV: microglial nodule (blue arrows); (g) ALZ + EDV group received 3 mg/kg of ICV-STZ in 48 hours interval; 24 hours later administered with 10 mg/kg of EDV: there was no damage; (h) ALZ + DON groups received 3 mg/kg of ICV-STZ+1 mg/kg of Donepezil: microglial nodule (blue arrows); (i) ALZ + Memantine group received 3 mg/kg of ICV-STZ + Memantine group received 5 mg/kg of Memantine: microglial nodule (blue arrows).